Belimumab
BENLYSTA
B Lymphocyte Stimulator-specific Inhibitor
NADAC/unit
N/A
No Shortage
Tier 1: 35.9%
PA Req: 198.2%
BENLYSTA is indicated for the treatment of patients 5 years of age and older with: • Active systemic lupus erythematosus (SLE) who are receiving standard therapy, and • Active lupus nephritis who a....
Market Intelligence
2025-07-30 Class II Recall: Mckesson Medical-Surgical Inc. Corporate Office
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.